Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma

The loss of functional von Hippel–Lindau (VHL) tumor suppressor gene is associated with the development of clear-cell renal cell carcinoma (CC-RCC). Recently, VHL was shown to promote the transcription of E-cadherin, an adhesion molecule whose expression is inversely correlated with the aggressive phenotype of numerous epithelial cancers. Here, we performed immunohistochemistry on CC-RCC tissue microarrays to determine the prognostic value of E-cadherin and VHL with respect to Fuhrman grade and clinical prognosis. Low Fuhrman grade and good prognosis associated with positive VHL and E-cadherin immunoreactivity, whereas poor prognosis and high-grade tumors associated with a lack of E-cadherin and lower frequency of VHL staining. A significant portion of CC-RCC with positive VHL immunostaining correlated with nuclear localization of C-terminally cleaved E-cadherin. DNA sequencing revealed in a majority of nuclear E-cadherin-positive CC-RCC, subtle point mutations, deletions and insertions in VHL. Furthermore, nuclear E-cadherin was not observed in chromophobe or papillary RCC, as well as matched normal kidney tissue. In addition, nuclear E-cadherin localization was recapitulated in CC-RCC xenografts devoid of functional VHL or reconstituted with synthetic mutant VHL grown in SCID mice. These findings provide the first evidence of aberrant nuclear localization of E-cadherin in CC-RCC harboring VHL mutations, and suggest potential prognostic value of VHL and E-cadherin in CC-RCC.

[1]  E. Voest,et al.  Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain* , 2005, Journal of Biological Chemistry.

[2]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[3]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[4]  W. Jiang,et al.  Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[6]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[7]  P. Rehak,et al.  Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases , 2004, Modern Pathology.

[8]  K. Moon,et al.  Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. , 2006, Archives of pathology & laboratory medicine.

[9]  B. de Strooper,et al.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Malpica,et al.  C-met proto-oncogene expression in benign and malignant human renal tissues. , 1997, The Journal of urology.

[11]  B. Curti Renal cell carcinoma. , 2004, JAMA.

[12]  S. Serra,et al.  Nuclear expression of E-cadherin. , 2008, The American journal of surgical pathology.

[13]  W. Kaelin,et al.  Molecular basis of the VHL hereditary cancer syndrome , 2002, Nature Reviews Cancer.

[14]  W. Kaelin,et al.  Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity , 2002, Molecular and Cellular Biology.

[15]  Ying Huang,et al.  Expression of Adipose Differentiation-Related Protein: A Predictor of Cancer-Specific Survival in Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.

[16]  J. Frydman,et al.  The Hsp70 and TRiC/CCT Chaperone Systems Cooperate In Vivo To Assemble the Von Hippel-Lindau Tumor Suppressor Complex , 2003, Molecular and Cellular Biology.

[17]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[18]  M. Ohh,et al.  The Role of VHL in the Regulation of E-Cadherin: A New Connection in an Old Pathway , 2007, Cell cycle.

[19]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[20]  G. Semenza,et al.  Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. , 2006, Cancer research.

[21]  W. H. Porter,et al.  Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer , 1999, British Journal of Cancer.

[22]  C. Damsky,et al.  Soluble 80‐kd fragment of cell‐CAM 120/80 disrupts cell‐cell adhesion , 1987, Journal of cellular biochemistry.

[23]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[24]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Comoglio,et al.  Overexpression of the met/HGF receptor in renal cell carcinomas , 1996, International journal of cancer.

[26]  W. Kaelin,et al.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Pienta,et al.  The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.

[29]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[31]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[32]  R. Kemler,et al.  Presenilin-dependent processing and nuclear function of gamma-protocadherins. , 2005, The Journal of biological chemistry.

[33]  Sarah K. Johnson,et al.  Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E‐cadherin , 2007, Cancer.

[34]  M. Ohh,et al.  Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[36]  M. Mareel,et al.  Plasmin Produces an E-Cadherin Fragment That Stimulates Cancer Cell Invasion , 2002, Biological chemistry.

[37]  M. Jewett,et al.  Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma , 2005 .

[38]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[39]  Y. Doki,et al.  Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. , 1998, British Journal of Cancer.

[40]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[41]  I. Shih,et al.  Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .

[42]  G. Serban,et al.  A presenilin‐1/γ‐secretase cleavage releases the E‐cadherin intracellular domain and regulates disassembly of adherens junctions , 2002, The EMBO journal.

[43]  M. Nakao,et al.  Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of β-catenin from cell – cell contacts , 1999, Oncogene.

[44]  Richard D Klausner,et al.  VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. , 2002, Cancer research.

[45]  P. Lara,et al.  Renal cell carcinoma: current status and emerging therapies. , 2007, Cancer treatment reviews.

[46]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[47]  O. Huber,et al.  Cleavage and Shedding of E-cadherin after Induction of Apoptosis* , 2001, The Journal of Biological Chemistry.

[48]  R. Raval,et al.  Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. , 2006, Cancer research.

[49]  K. Nakagawa,et al.  Soluble E-cadherin fragments increased in circulation of cancer patients. , 1994, British Journal of Cancer.

[50]  G. Berx,et al.  VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail , 2006, Molecular and Cellular Biology.

[51]  D. Fishman,et al.  Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. , 2007, Cancer research.

[52]  B. Seizinger,et al.  Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.

[53]  H. Kawamata,et al.  Biological role of HGF/MET pathway in renal cell carcinoma. , 1999, The Journal of urology.

[54]  G. Carpenter Nuclear localization and possible functions of receptor tyrosine kinases. , 2003, Current opinion in cell biology.

[55]  R. Klausner,et al.  The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[56]  Y. Nagashima,et al.  Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. , 2006, Cancer research.

[57]  A. P. Soler,et al.  Nuclear localization of E-cadherin expression in Merkel cell carcinoma. , 2000, Archives of pathology & laboratory medicine.

[58]  M. Fortini,et al.  Signalling: γ-Secretase-mediated proteolysis in cell-surface-receptor signalling , 2002, Nature Reviews Molecular Cell Biology.

[59]  P. Troncoso,et al.  c-met proto-oncogene expression in benign and malignant human prostate tissues. , 1995, The Journal of urology.

[60]  Tian-Li Wang,et al.  Notch signaling, gamma-secretase inhibitors, and cancer therapy. , 2007, Cancer research.

[61]  W. Kaelin,et al.  The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.

[62]  E. Choi,et al.  Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells , 2007, European Surgical Research.

[63]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[64]  V. Thulasiraman,et al.  Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. , 1999, Molecular cell.

[65]  R. Kemler,et al.  Presenilin-dependent Processing and Nuclear Function of γ-Protocadherins* , 2005, Journal of Biological Chemistry.

[66]  J. Patard,et al.  Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Joyce,et al.  Cysteine Cathepsins and the Cutting Edge of Cancer Invasion , 2007, Cell cycle.

[68]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[69]  E. Choi,et al.  Change of E-Cadherin by Hepatocyte Growth Factor and Effects on the Prognosis of Hypopharyngeal Carcinoma , 2007, Annals of Surgical Oncology.

[70]  B. Gumbiner,et al.  Regulation of Cadherin Adhesive Activity , 2000, The Journal of cell biology.

[71]  R. Nusse,et al.  Convergence of Wnt, beta-catenin, and cadherin pathways. , 2004, Science.

[72]  P. Saftig,et al.  Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. , 2006, Pharmacology & therapeutics.